Full Prescribing Information, Including Boxed Warning
For US healthcare professionals only
FDA Approved

Available Soon

GRAFAPEX™ (treosulfan) for Injection is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients >1 year old with AML or MDS.

Explore GRAFAPEX full Prescribing Information

See how GRAFAPEX compares to Busulfan in overall survival.

Explore the full Prescribing Information for more details.

AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.

GRAFAPEX will be available to prescribe soon.
Sign up to receive updates.

For US healthcare professionals only.

Indications, Important Safety Information, Including Boxed Warning, for GRAFAPEX™ (treosulfan) for Injection

Indications and Usage

Acute Myeloid Leukemia: GRAFAPEX is an alkylating drug indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients >1 year old with acute myeloid leukemia.

Myelodysplastic Syndrome: GRAFAPEX is an alkylating drug indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients >1 year old with myelodysplastic syndrome.

This product includes the following Boxed Warning:

WARNING: MYELOSUPPRESSION

  • GRAFAPEX causes severe and prolonged myelosuppression at the recommended dosage.
  • Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters.

Warnings and Precautions

Myelosuppression: Profound myelosuppression with pancytopenia is the desired therapeutic effect of a GRAFAPEX-based preparative regimen, occurring in all patients. Do not begin the preparative regimen if the stem cell donor is not available. Monitor blood cell counts at least daily until hematopoietic recovery. Provide standard supportive care for infections, anemia, and thrombocytopenia until there is adequate hematopoietic recovery.

Seizures: Monitor patients for signs of neurological adverse reactions, including seizure. Clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants.

Skin Disorders: An increase in skin disorders (eg, rash, dermatitis) was observed when patients received sodium bicarbonate–containing hydration in the course of treosulfan infusion. Keep skin clean and dry on days of GRAFAPEX infusion. Diaper dermatitis may occur because of excretion of treosulfan in the urine. Change diapers frequently during the 12 hours after each infusion of GRAFAPEX. Dermatitis may occur under occlusive dressings; change occlusive dressings after each infusion of GRAFAPEX.

Injection Site Reactions and Tissue Necrosis: Treosulfan may cause local tissue necrosis and injection site reactions, including erythema, pain, and swelling, in cases of extravasation. Assure venous access patency prior to starting GRAFAPEX infusion, and monitor the intravenous infusion site for redness, swelling, pain, infection, and necrosis during and after administration of GRAFAPEX. If extravasation occurs, stop the infusion immediately and manage medically as required. Do not administer by intramuscular or subcutaneous routes.

Secondary Malignancies: There is an increased risk of a secondary malignancy with the use of GRAFAPEX. Treosulfan is carcinogenic and genotoxic.

The risk of secondary malignancy is increased in patients with Fanconi anemia and other DNA breakage disorders. The safety of GRAFAPEX has not been established for patients with these disorders.

Increased Early Morbidity and Mortality at Dosages Higher Than Recommended: Higher incidence of early fatal and/or serious adverse reactions has been observed in patients receiving treosulfan at dosages of 14 g/m2 (1.4 times the recommended dose). Avoid exceeding the recommended GRAFAPEX dosage of 10 g/m2 daily for three consecutive days.

Embryo-Fetal Toxicity: GRAFAPEX can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

The most common adverse reactions (≥20%) in patients treated with GRAFAPEX were musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. Select Grade 3 or 4 nonhematological laboratory abnormalities were increased GGT, increased bilirubin, increased ALT, increased AST, and increased creatinine.

Drug Interactions

Effect of GRAFAPEX on Other Drugs (Certain CYP2C19 and CYP3A Substrates): Concomitant use of GRAFAPEX is predicted to increase the exposure of CYP2C19 and CYP3A4 substrates based on a mechanistic understanding of treosulfan metabolism, which may increase the risk of adverse reactions.

Use in Specific Populations

  • Pregnancy: GRAFAPEX can cause fetal harm. There are no available human clinical data on the use of treosulfan in pregnant women to support an estimation of a drug-associated risk. Specific embryo-fetal developmental toxicity studies with treosulfan in animals were not conducted.
  • Lactation: There is no data on the presence of treosulfan or its metabolites in human milk, its effects on milk production, or the effects of treosulfan on the breastfed child. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with GRAFAPEX and for at least 1 week after the last dose.
  • Patients With Renal Impairment: No dosage adjustment is recommended for patients with mild renal impairment (creatinine clearance [CLcr] 60–89 mL/min). The effect of moderate or severe renal impairment and age >65 years on GRAFAPEX pharmacokinetics is unknown.
  • Pediatric Use: The safety profile in children 1 year of age and older is comparable to that seen in adult patients, except that the incidence of hepatic and gastrointestinal toxicities was higher in pediatric patients than in adults.
  • Geriatric Use: No significant differences in safety or effectiveness were observed between elderly subjects and younger subjects.
  • Hepatic Impairment: No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin less than or equal to upper limit of normal [ULN] with aspartate aminotransferase [AST] greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST). The effect of moderate or severe hepatic impairment and age >65 years on GRAFAPEX pharmacokinetics is unknown.

For adverse events, medical inquiries, and GRAFAPEX product-related concerns, please call 1-855-336-3322.
This site is intended for US residents only.

Accessibility

While every effort is made to ensure the accuracy of translation, Medexus Pharma, Inc., assumes no liability for damage or loss caused by any error, inaccuracy, or misunderstanding with regard to this translation.

Web Accessibility Statement

General

Medexus Pharma, Inc., cares about all of our customers and is committed to facilitating and improving the accessibility and usability of our websites, ensuring that our website services and content are accessible to persons with disabilities including, but not limited to, users of screen reader technology.

Please be aware that our efforts to maintain accessibility and usability are ongoing. While we strive to make the website as accessible as possible, some issues may be encountered by different assistive technology as the range of assistive technology is wide and varied. We appreciate your understanding.

Disclaimer

Please be aware that our efforts to maintain accessibility and usability are ongoing. While we strive to make the website as accessible as possible, some issues may be encountered by different assistive technology as the range of assistive technology is wide and varied. We appreciate your understanding.

Contact Us

If, at any time, you have specific questions or concerns about the accessibility of any particular web page on the website, then please contact us at https://www.medexus.com/en_US/contact. If you do encounter an accessibility issue, then please be sure to specify the web page and nature of the issue, and we will make all reasonable efforts to make that page or the information contained therein accessible for you. Thanks for visiting.

Terms of Use

LEGAL TERMS OF USE

THIS WEBSITE, WHICH IS ACCESSIBLE UNDER THE DOMAIN NAME GRAFAPEX.COM, IS MAINTAINED BY MEDEXUS PHARMA, INC., A DELAWARE CORPORATION. THE INFORMATION CONTAINED ON THIS WEBSITE, INCLUDING ANY INFORMATION REGARDING PRODUCTS OF MEDEXUS PHARMA, INC., IS INTENDED SOLELY FOR RESIDENTS OF THE UNITED STATES.

Your access to and use of the materials and information contained on this website are subject to the following terms and conditions. If you choose to access the website or make use of any of the information or materials it contains, you agree to be bound by these terms. If you do not accept these terms, do not use this website.

Proprietary Materials

The content appearing on this website is protected by copyright. You may view and copy materials and information on the website solely for your own non-commercial, personal, and informational use. All copyright and other proprietary notices appearing on the website must be retained on any copies you make. No other use of the content provided on the website is authorized and is therefore expressly prohibited.

In addition, all trademarks and logos displayed on the website are the property of Medexus Pharma, Inc. You are not permitted to use these trademarks or logos without the prior written permission of Medexus Pharma, Inc.

Third-Party Websites

INFORMATION PERTAINING TO THE BUSINESS PARTNERS OF MEDEXUS PHARMA, INC., INCLUDING ITS PARENT COMPANY, MEDEXUS PHARMA, IS AVAILABLE THROUGH THE SEPARATE WEBSITES OF THOSE PARTIES.

Medexus Pharma, Inc., may provide links to websites operated by other parties, including the business partners of Medexus Pharma, Inc., as a convenience to the users of this website. Such third-party websites are not under the control of Medexus Pharma, Inc., and Medexus Pharma, Inc., is not responsible for the content of any third-party website.

Disclaimers and Limitation of Liability

The statements and all materials contained on this website are provided for your general information only. The information is not intended to provide medical advice or patient-specific treatment advice. Users of this website should be aware that products described on this website have not yet been approved for use in the United States.

Although Medexus Pharma, Inc., uses reasonable efforts to provide correct and current information on this website, the company assumes no responsibility for the accuracy or reliability of the information. The information and materials contained on the website at times may become out of date or may include omissions or other errors. Medexus Pharma, Inc., may change the information provided on the website at any time without notice.

All information provided on this website is provided “AS IS” and without any warranty of any kind, either express or implied, including any implied warranties of merchantability, fitness for a particular purpose or non-infringement of third-party rights, in each case to the fullest extent permitted by law.

Medexus Pharma, Inc., and its agents will not be liable for any direct, indirect, incidental, consequential, special, or punitive damages arising out of your use of the website or the materials, information, or links it contains.

Inquiries

Any information you choose to submit to Medexus Pharma, Inc., through this website or by using an email address appearing on this website will be treated by Medexus Pharma, Inc., in accordance with the privacy policy for this website.

Updates

Medexus Pharma, Inc., reserves the right to amend these terms of use from time to time, and an updated version of the applicable terms of use will reflect those changes. Medexus Pharma, Inc., will provide prior notice of any changes to the terms of use and will update the effective date listed in the applicable terms of use.

Effective November 21, 2022.